Tuesday, 17 November 2026European Markets

PHARMING GROUP Stock Impressive Drop 13% So Far On Thursday, Underperforms Market

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(VIANEWS) - Shares of PHARMING GROUP (AEX-Index: PHARM.AS) fell by a staggering 13.16% to €1.02 at 11:08 EST on Thursday, after five sequential sessions in a row of gains. AEX-Index is jumping 0.84% to €754.57, after two consecutive sessions in a row of losses. This seems, up until now, a somewhat positive trend trading session today.

About PHARMING GROUP

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Earnings Per Share

As for profitability, PHARMING GROUP has a trailing twelve months EPS of €0.02.

PE Ratio

PHARMING GROUP has a trailing twelve months price to earnings ratio of 51.15. Meaning, the purchaser of the share is investing €51.15 for every euro of annual earnings.

Volume

Today's last reported volume for PHARMING GROUP is 19241711 which is 79.07% above its average volume of 10744900.

More news about PHARMING GROUP (PHARM.AS).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

  1. Published before we listed source documents with each article.
  2. Published 11 May 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›